Park et al., 2016 - Google Patents
High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute …Park et al., 2016
View PDF- Document ID
- 13066563227398593023
- Author
- Park J
- Lee H
- Kee Y
- Park S
- Oh H
- Han S
- Joo K
- Lim C
- Kim Y
- Kang S
- Yoo T
- Kim D
- Jo H
- Han M
- Lee S
- Kim E
- Yang J
- Lee M
- Kwon Y
- Park K
- Han S
- Han I
- Yoon C
- Ryu G
- Jhee J
- Kim H
- Park S
- Jung S
- Kim E
- Kim M
- Kim Y
- Jang Y
- Kim M
- Song K
- Kim M
- Hyun J
- Choi B
- Publication year
- Publication venue
- American Journal of Kidney Diseases
External Links
Snippet
Background Soluble inflammatory mediators are known to exacerbate sepsis-induced acute kidney injury (AKI). Continuous renal replacement therapy (CRRT) has been suggested to play a part in immunomodulation by cytokine removal. However, the effect of continuous …
- 206010038436 Renal failure acute 0 title abstract description 54
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. haemofiltration, diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. haemofiltration, diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | High-dose versus conventional-dose continuous venovenous hemodiafiltration and patient and kidney survival and cytokine removal in sepsis-associated acute kidney injury: a randomized controlled trial | |
| Kogelmann et al. | Hemoadsorption by CytoSorb in septic patients: a case series | |
| Karkar et al. | Prescription of CRRT: a pathway to optimize therapy | |
| Morgera et al. | Renal replacement therapy with high-cutoff hemofilters: impact of convection and diffusion on cytokine clearances and protein status | |
| Shiga et al. | Continuous hemodiafiltration with a cytokine-adsorbing hemofilter in patients with septic shock: a preliminary report | |
| Schefold et al. | The effect of continuous versus intermittent renal replacement therapy on the outcome of critically ill patients with acute renal failure (CONVINT): a prospective randomized controlled trial | |
| Dellepiane et al. | Detrimental cross-talk between sepsis and acute kidney injury: new pathogenic mechanisms, early biomarkers and targeted therapies | |
| Peng et al. | Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis | |
| Krishnasamy et al. | A trial evaluating mid cut-off value membrane clearance of albumin and light chains in hemodialysis patients: a safety device study | |
| Kim et al. | Removal of large middle molecules via haemodialysis with medium cut-off membranes at lower blood flow rates: an observational prospective study | |
| Yang et al. | Hypophosphatemia during continuous veno-venous hemofiltration is associated with mortality in critically ill patients with acute kidney injury | |
| Chu et al. | Clinical effects of pulse high‐volume hemofiltration on severe acute pancreatitis complicated with multiple organ dysfunction syndrome | |
| Guru et al. | Association of thrombocytopenia and mortality in critically ill patients on continuous renal replacement therapy | |
| Kee et al. | The effect of specialized continuous renal replacement therapy team in acute kidney injury patients treatment | |
| Lumlertgul et al. | Clearance of inflammatory cytokines in patients with septic acute kidney injury during renal replacement therapy using the EMiC2 filter (Clic-AKI study) | |
| Maxwell et al. | Acute kidney injury in the critically ill | |
| Singh | Acute kidney injury after pediatric cardiac surgery | |
| Oh et al. | Can early initiation of continuous renal replacement therapy improve patient survival with septic acute kidney injury when enrolled in early goal-directed therapy? | |
| Goldstein et al. | Use of the selective cytopheretic device in critically ill children | |
| Weidhase et al. | Middle molecule clearance with high cut-off dialyzer versus high-flux dialyzer using continuous veno-venous hemodialysis with regional citrate anticoagulation: a prospective randomized controlled trial | |
| Abe et al. | Comparison of sustained hemodiafiltration with continuous venovenous hemodiafiltration for the treatment of critically ill patients with acute kidney injury | |
| Hafner et al. | Implementation of continuous renal replacement therapy with regional citrate anticoagulation on a surgical and trauma intensive care unit: impact on clinical and economic aspects—an observational study | |
| Li et al. | Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta‐analysis of randomized controlled trials | |
| Lim et al. | High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration | |
| Thanapongsatorn et al. | Citrate pharmacokinetics in critically ill liver failure patients receiving CRRT |